trending Market Intelligence /marketintelligence/en/news-insights/trending/hUFIFH6twlnPga2Y3QkWgw2 content esgSubNav
In This List

Ritter reports positive results in phase 2b/3 trial of lactose intolerance drug

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Commercial Banking Newsletter June Edition - 2022

Blog

Insight Weekly: US recession outlook; mortgage activity slowdown; climate disclosure push


Ritter reports positive results in phase 2b/3 trial of lactose intolerance drug

Ritter Pharmaceuticals Inc. reported positive topline results from the phase 2b/3 clinical trial evaluating RP-G28 in subjects with lactose intolerance.

The study showed "clinically meaningful benefit" by reducing lactose intolerance symptoms in subjects. The primary endpoint met statistical significance, in which 40% of the pooled dosing group and 26% of the placebo group responded.

There were no significant adverse events reported from the use of the treatment.

Ritter intends to discuss the trial's results with the U.S. FDA and the design of a confirmatory phase 3 trial at an upcoming end-of-phase 2 meeting.

The company will then submit a new drug application upon the completion of its planned phase 3 study of RP-G28.